These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 33897892)

  • 1. Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101.
    Bao X; Shen N; Lou Y; Yu H; Wang Y; Liu L; Tang Z; Chen X
    Theranostics; 2021; 11(12):5955-5969. PubMed ID: 33897892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma.
    Wang Y; Yu H; Zhang D; Wang G; Song W; Liu Y; Ma S; Tang Z; Liu Z; Sakurai K; Chen X
    Acta Biomater; 2019 Jul; 92():229-240. PubMed ID: 31100462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma.
    Zhao B; Dong Z; Liu W; Lou F; Wang Q; Hong H; Wang Y
    J Nanobiotechnology; 2021 May; 19(1):124. PubMed ID: 33933077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment.
    Shen N; Wu J; Yang C; Yu H; Yang S; Li T; Chen J; Tang Z; Chen X
    Nano Lett; 2019 Nov; 19(11):8021-8031. PubMed ID: 31558024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
    Shigeta K; Datta M; Hato T; Kitahara S; Chen IX; Matsui A; Kikuchi H; Mamessier E; Aoki S; Ramjiawan RR; Ochiai H; Bardeesy N; Huang P; Cobbold M; Zhu AX; Jain RK; Duda DG
    Hepatology; 2020 Apr; 71(4):1247-1261. PubMed ID: 31378984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Effects of Nanoscale CaO
    Wang Y; Ju S; Zhou H; Bai Y; Zhou C; Liu J; Dong X; Zheng C
    Int J Nanomedicine; 2024; 19():137-154. PubMed ID: 38196507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
    Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T
    Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
    Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor regression and potentiation of polymeric vascular disrupting therapy through reprogramming of a hypoxia microenvironment with temsirolimus.
    Yu H; Shen N; Bao Y; Chen L; Tang Z
    Biomater Sci; 2020 Jan; 8(1):325-332. PubMed ID: 31714543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma.
    Guo L; Li H; Fan T; Ma Y; Wang L
    Life Sci; 2021 Aug; 279():119359. PubMed ID: 33753114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formula optimization and in vivo study of poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/combretastatin A4/BLZ945 nanoparticles for cancer therapy.
    Huang Y; Yang C; Lv J; Zhang Y; Wang K; Ma L; Liu Z; Yu H; Li M; Tang Z
    Int J Pharm; 2023 Apr; 636():122849. PubMed ID: 36933582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxia-Activated Prodrug Tirapazamine Therapy for Metastatic Tumors.
    Yang S; Tang Z; Hu C; Zhang D; Shen N; Yu H; Chen X
    Adv Mater; 2019 Mar; 31(11):e1805955. PubMed ID: 30680816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine.
    Shi W; Yang X; Xie S; Zhong D; Lin X; Ding Z; Duan S; Mo F; Liu A; Yin S; Jiang X; Xu ZPG; Lu X
    Cancer Lett; 2021 Dec; 522():184-197. PubMed ID: 34562519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FXIIIa substrate peptide decorated BLZ945 nanoparticles for specifically remodeling tumor immunity.
    Wei Q; Shen N; Yu H; Wang Y; Tang Z; Chen X
    Biomater Sci; 2020 Oct; 8(20):5666-5676. PubMed ID: 33049011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
    Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
    Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
    Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Chimeric Cetuximab-Functionalized Corona as a Potent Delivery System for Microtubule-Destabilizing Nanocomplexes to Hepatocellular Carcinoma Cells: A Focus on EGFR and Tubulin Intracellular Dynamics.
    Poojari R; Kini S; Srivastava R; Panda D
    Mol Pharm; 2015 Nov; 12(11):3908-23. PubMed ID: 26426829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
    Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment.
    Sasaki T; Shigeta K; Kitahara S; Suzuki Y; Matsui S; Seishima R; Okabayashi K; Duda DG; Kitagawa Y
    Anticancer Res; 2022 Nov; 42(11):5205-5215. PubMed ID: 36288859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.